Skip to main content
Clinical Trials/ACTRN12609000571279
ACTRN12609000571279
Completed
Phase 3

Prospective non controlled study of immunogenicity of Human Papilloma Virus (HPV) Vaccine in groups at special risk of poor vaccine result

ational Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation0 sites100 target enrollmentJuly 13, 2009

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Special Risk Groups1. Paediatric Rheumatalogical Disease2. Inflammatory Bowel Disease3. Acute Lymphoblastic Leukaemia4. Solid Organ Transplant Recipients (kidney and liver)5. Chronic Renal Disease6. Bone Marrow TranssplantThe response to the HPV vaccine will be studied within these 6 special risk groups.
Sponsor
ational Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation
Enrollment
100
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 13, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
ational Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation

Eligibility Criteria

Inclusion Criteria

  • Females aged 12\-26 years
  • Have been diagnosed by a specialist with one of the six chronic medical conditions described.
  • Special Risk Groups
  • 1\. Paediatric Rheumatalogical Disease
  • 2\. Inflammatory Bowel Disease
  • 3\. Acute Lymphoblastic Leukaemia
  • 4\. Solid Organ Transplant Recipients (kidney and liver)
  • 5\. Chronic Renal Disease
  • 6\. Bone Marrow Transsplant

Exclusion Criteria

  • Previous immunisation with HPV vaccine
  • Recognised contraindication to the receipt of the vaccine e.g. anaphylaxis

Outcomes

Primary Outcomes

Not specified

Similar Trials